More specifically, the 5-year survival rate of patients with advanced NSCLC treated with ICIs has been shown to exceed 15%.[11,12]Although predictive biomarkers of ICIs remain unknown, PD-L1 expression in both tumor and immune cells has been reported to correlate with treatment outcomes in NSCLC patients.[13,14]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.